Drug intelligence / Profile preview

vinorelbine + gemcitabine + carboplatin

Development stage: Preclinical
Lead developer: Pierre Fabre
Modality: Small Molecules
Administration: Intravenous

Overview

A chemotherapy combination regimen consisting of vinorelbine (a vinca alkaloid), gemcitabine (a nucleoside analog), and carboplatin (a platinum compound). This triple combination is used primarily in the treatment of non-small cell lung cancer (NSCLC). Vinorelbine is a semi-synthetic vinca alkaloid that works by inhibiting microtubule assembly, thereby preventing cell division. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and carboplatin is a platinum-based compound that forms DNA adducts, interfering with DNA replication and transcription.

Targets

DNA polymerase familyDNARNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on vinorelbine + gemcitabine + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vinorelbine + gemcitabine + carboplatin.

Explore the full profile